Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ironwood Could Use Linzess As Model For GERD Market

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The biotech has moved into mid-stage studies with a heartburn drug that will face OTC competition, much like Linzess has battled with in the area of constipation.

You may also be interested in...



Ironwood Hits Endpoints In GERD, But Analysts Unimpressed With Treatment Effect

The GI specialty firm hopes it has a future blockbuster with the bile acid sequestrant after hitting multiple endpoints in Phase IIb, but the treatment effect compared to PPI therapy alone was below what was previously anticipated.

Ironwood/Forest Hoping To Change The Conversation About Constipation

The partners began a DTC campaign to promote their constipation drug and ease the conversation between physicians and patients about the often embarrassing condition.

Nexium OTC Switch Would Face Crowded Field, Potential Questions

Pfizer will pay AstraZeneca $250 million upfront for global rights to market a potential OTC 20-mg Nexium. Pharma marketing expert Joe McGovern expects Nexium “to start OTC with a big bang,” but Center for Consumer Self Care Executive Director Bill Soller points to potential safety questions about a switch.

Topics

Related Companies

UsernamePublicRestriction

Register

PS005873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel